

ICPerMed "Best Practice in PM" Recognition 2019

Gaetano Guglielmi

and IT-MoH IcPermed Sec. Team

Maria Grazia Mancini

Maria Josefina Ruiz Alvarez

Italian Ministry of Health

2nd ICPerMed Workshop Madrid
5th November 2019



ICPerMed Best Practise Recognition 2019 – 2nd call

- Launched on 21st of November 2018.
- Deadline for proposal submission was 21st of January, with an extension until 4th February 2019
- Opened to applicants worldwide.

Responsible authors (applicants from any countries) of candidate proposal published and/or developed between January 1st, 2017 and October 31st, 2018 were eligible to apply.

- Call topics have been aligned to [contents of Madrid Workshop 2019 “ PM for all citizens and patients within Sustainable Implementation”](#)

The winner(s) are invited to the Madrid ICPeMed Workshop 2019 and are given the opportunity to present their results during a plenary session to stakeholders interested in the area of PM.

In addition, the successful candidates will receive a non – cash support for the dissemination of the best practice example by the ICPeMed Secretariat in the value of € 500

Main Topic and defined areas:

- The applications received covers one or more than one of the three defined areas:
- 1. **Scientific paper** focused on novel approaches for the implementation of PM
- 2. **Training programmes** for health personnel, increasing the level of awareness on the potential of PM
- 3. **Examples for interdisciplinary or intersectoral groups of collaboration** (governmental and nongovernmental organizations, academic management, medical research and Health Care), for the implementation of PM, including Ethical, Legal and Social Issues (ELSI) activities

ICPerMed Recognition 2019



Overview Proposals

Total Number of arrived: 38

Number of proposals arrived at the first deadline (21th january 2019): 24


Number of proposals arrived at the second deadline (4th february 2019): 14

Applicants: Gender Distribution




ICPerMed Best Practise Recognition 2019 – 2nd call

APPLICANTS GROUPS:




Selection Areas:



1. Scientific paper : Novel approaches for the implementation of PM
2. Training programmes for health personnel
3. Examples for interdisciplinary or intersectoral groups of collaboration

ICPerMed Recognition 2019: focus disease



Oncology , Chronic Disease, Neurology

ICPerMed Recognition 2019:REVIEWERS

Experts contacted to evaluate the proposals : 31

- No answer: 12
- Answer no : 4
- Answer yes: 15
- Final collaboration: 12

Evaluator	Name	Expertise
1	Prof. Valérie BARBIÉ	Bioinformatic
2	Dr. Jose A. BARRABES	Cardiovascular
3	Dr. Maria Luís CARDOSO	Pharmacogenomic
4	Prof. Anna Rita Franco Migliaccio	Bioscience
5	Prof. Roberta Gualtierotti	Inmunodisease
6	Dr. Philipp Hofer	Clinical Innovation
7	Dr.Catalina Lopez Correa	Genomic Public Health
8	Dr. Inma Maestu Maiques	Clinical Oncology
9	Dr.Fernando Martin Sanchez	Biomedical Informatics
10	Dr. Barbara Prainsack	Global Health
11	Dr. Marta Puyol Escobar	Patient association
12	Dr. Giovanni Tonon	Genomic oncology

ICPerMed Best Practise Recognition 2019 – 2nd call

Evaluation Guideline:

- One stage process by consulting high-level scientists in the field
- Supported by ICPerMed Secretariat. The final decision will be made by the ICPerMed Executive Committee.
- The It-MoH (on behalf of ICPerMed Secretariat) and the Steering Board are responsible for the management of the evaluation process.
- The applicants will be informed about the decisions individually by the ICPerMed Secretariat (It-MoH)

Evaluation Criteria

- 1.- Knowledge Production
 - 2.- Research capacity-building and targeting
 - 3.- Informing policy and practice
 - 4.- Population health and health sector benefits
 - 5.-Economic impacts
-
- For each criterion, your proposal will be given scores of 1 to 5 (half marks are possible).
-
- Total Score: 1-5 THRESHOLD >2

Certificate of Best Practise Recognition ICPerMed 2019

This certificated is awarded to

.....

for winning the first / second/ place
in the ICPerMed "Best Practice in Personalised Medicine"
Recognition 2019

publicized by The International Consortium for Personalised Medicine (ICPerMed).




SELECTED PROPOSALS

SELECTED PROPOSAL FOR PRESENTATION DURING PLENARY SECTION

first author	institution	Other authors	Title / Defined Areas
Patrizio Giacomini	Oncogenomics & Epigenetics, IRCSS National Cancer Institute Regina Elena, Rome, Italy	No	A Liquid Biopsy ‘hub’: integrating Nano-technologies to improve cancer diagnosis and therapy Area 1,2,3
Juergen Busch	Ludwig Boltzmann Gesellschaft, Austria	Gertraud Leimueller, winnovation – Open Innovation Research ; L..Malfent, L. Boltzmann Gesellschaft; J. Niebauer, Paracelsus Medical University & University Hospital Salzburg; H. Willschke, Medical University & University Hospital Vienna, Austria	Best Open Innovation in Science Practice for the Establishment of Interdisciplinary & Inter-Sectoral Collaboration. Platforms for the Implementation of PM. Ludwig Boltzmann Institutes for Digital Health Area 3
Sulev Resiberg	Univesity Tartu STACC, Quretec, Estonia	Kristi Krebs, Maarja Lepamets, Mart Kals, Reedik Magi, Kristjan Metsalu, U. Tartu, Quretec, Estonia ; Volker M.Lauschke, Karoslinska Institutet Sweden; Jaak Vilo, Univesity Tartu, Quretec, Estonia; Lili Milani, Univesity Tartu, Quretec, Estonia	Translating genotype data into clinical pharmacogenetic recommendations: challenges and solutions Area 1
Mark A.Rubin	Department of BioMedical Research (DBMR), University of Bern, Switzerland	No	Development and integration of organoid models in personalised medicine platforms Area 1

first author	institution	Other authors	Title / Area
Patrizio Giacomini	Oncogenomics & Epigenetics, IRCSS National Cancer Institute Regina Elena, Rome, Italy	No	A Liquid Biopsy ‘hub’: integrating Nano-technologies to improve cancer diagnosis and therapy Area 1,2,3

Dr. Giacomini long term goal is to take advantage of biotechnology, in particular nanotechnology, to make therapy assignment more precise and drugs more cancer-specific and hence less toxic. He works in the Molecular Tumor Board (MTB) of the Regina Elena Cancer Institute in Rome. The MTB, like other MTBs that are being created in comprehensive cancer centers worldwide, is a multidisciplinary organism aiming at extending the benefit of new targeted therapies to the largest possible population of people with cancer. MTBs search cancer genomes for novel vulnerabilities, and determine whether patients who have failed many therapy lines are still likely to respond to additional non-standard drugs.



first author	institution	Other authors	Title / Area
Juergen Busch	Ludwig Boltzmann Gesellschaft, Austria	Gertraud Leimueller, winnovation – Open Innovation Research ; L..Malfent, L. Boltzmann Gesellschaft; J. Niebauer, Paracelsus Medical University & University Hospital Salzburg; H. Willschke, Medical University & University Hospital Vienna, Austria	Best Open Innovation in Science Practice for the Establishment of Interdisciplinary & Inter-Sectoral Collaboration. Platforms for the Implementation of PM. Ludwig Boltzmann Institutes for Digital Health Area 3

Juergen Busch is research director for SSh and Helath Sciences at the Ludwig Boltzmann Gesellschaft (LBG) in Vienna. He is in charge of implementing a digital health and personalised medicine strategy at LBG. He studied history, political science, law, and legal theory in Vienna, Leuven, and Brussels and before joining the LBG, he held various research and (research) management positions at the Austrian Academy of Sciences (OeAW), the Universities of Vienna and Lucerne and the Austrian Agency for International Cooperation in Education and Research (OeAD. His own research is situated at the intersections of history and philosophy of law and legal theory.



first author	institution	Other authors	Title / Area
Sulev Resiberg	Univesity Tartu STACC, Quretec, Estonia	Kristi Krebs, Maarja Lepamets, Mart Kals, Reedik Magi, Kristjan Metsalu, U. Tartu, Quretec, Estonia ; Volker M.Lauschke, Karoslinska Institutet Sweden; Jaak Vilo, Univesity Tartu, Quretec, Estonia; Lili Milani, Univesity Tartu, Quretec, Estonia and University Uppsala, Sweden	Translating genotype data into clinical pharmacogenetic recommendations: challenges and solutions Area 1

Sulev Reisberg is a PhD student of bioinformatics at the University of Tartu. He has long experience of working with most of the Estonian health databases and his research is focusing on (big) health data analytics, including the genomics.



first author	institution	Other authors	Title / Area
Mark A.Rubin	Department of BioMedical Research (DBMR), University of Bern, Switzerland	No other authors	Development and integration of organoid models in personalised medicine platforms Area 1

Prof. Mark Rubin is a leader in the fields of prostate cancer biology and precision medicine as it applies to all cancers. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Prof. Rubin has translated many of his genomic discoveries into clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer. In May 2017, Prof. Rubin joined the University of Bern as Professor and Director of the Department for Biomedical Research and also as Leader for the newly founded Bern Center for Precision Medicine.



Selected proposal for the section of Poster

Dr. Dafna Ben Bashat, Israel «Personalized Radiology: Automatic Quantitative Assessment of Brain Tumors”

Dr. Yvonne Bombard, Canada «The Genomics ADVISER.com: An e-decision aid to support patients’ choices about learning their incidental results from genome sequencing.”

Dr. Stefania Boccia, Italy «How to integrate Personalized Medicine into Prevention? Recommendations from the Personalized pREvention of Chronic Diseases (PRECeDI) consortium”

Prof. Dom Dwyer, Germany “The NeuroMiner Machine Learning School Training Programme”

Prof. Stefan Fröhling, Germany «Cross-institutional implementation of comprehensive genomic analysis for personalized oncology: The MASTER initiative of the German Cancer Consortium”

Dr. Maris Alver, Estonia « Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia”

Dr. Nicola Gentili / Dr. Ilaria Massa, Italy “The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study) from a Personalized Medicine point-of-view”

Dr.ssa Vera Damuzzo, Italy «Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy”

ICPerMed Recognition 2020

The launch of the “BEST PRACTICE IN PERSONALISED MEDICINE” RECOGNITION 2020 will be on 5th of November 2019.

Deadline for proposal submission will be on 23th of January, 2020.

According to guidance of the ICPerMed Steering Board the call has been opened to [applicants worldwide](#).

Call topic have been aligned to [topics of Paris Conference 2020](#):

“Health systems enabling personally tailored and valuable health promotion, prevention, diagnosis and treatment”

ICPerMed Recognition 2020

Year	Date	Activity	Comments
2019	October 7th	Preliminary-Announcement	Website ICPerMed
2019	November 5th	Launch of the call	Website ICPerMed and 2 nd ICPerMed workshop Madrid
2020	January 23th	Deadline for presenting proposals	
2020	March 21th	Deadline for Evaluation/selection proposal	
2020	April	Selection communication	Website ICPerMed / ExCom Meeting
2020	October	Recognition selected applications presentation	ICPerMed Conference Paris

Thanks for your attention!

For more information:

Maria Grazia Mancini

mg.mancini-esterno@sanita.it

Maria Josefina Ruiz Alvarez

mj.ruizalvarez-esterno@sanita.it

DGRIC, Italian Ministry of Health



We wait your applications!!!